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Background: The effect of early antiretroviral therapy (ART) on sexual behaviors and HIV-1 
transmission risk has not been documented beyond the specific population of stable serodiscordant 
couples. 
Methods: Based on a behavioralstudy nested in a randomized controlled trial (Temprano-
ANRS12136) of early ART, we compared proportions of risky sex (unprotected sex with a partner of 
negative/unknown HIVstatus) reported 12 months after inclusion between participants randomized to 
initiate ART immediately (‗early ART‘) or according to WHO criteria (‗standard ART‘). Group-specific 
HIV-transmission rates were estimated based on sexual behaviors and viral load-specific per-act HIV-
1 transmission probabilities. Their ratio was computed to estimate the protective effect of early ART. 
Results: Among 957 participants (baseline CD4: 478/mm
3
), 46.0% reported sexual activity in the past 
month, 41.5% of them with non-cohabiting partners. Proportion of risky sex was10.0%vs. 12.8%, 
respectively, in participants on early vs. standard ART (p=0.17). Accounting for sexual behaviors and 
viral load, the estimated protective effect of early ART was 90% (95%CI 81-95%). 
Conclusion: Twelve months after inclusion,patients on early and standard ART reported similar 
sexual behaviors. Early ART decreased the estimated risk of HIV transmission by 90%, suggestinga 
major prevention benefit among both stable and casual partners. 
 
 
Key-words: HIV prevention; antiretroviral treatment; sexual behaviors; HIV-1 sexual 
transmission;Treatment as Prevention; epidemiology; sub-Saharan Africa 
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Introduction 
By controlling viral replication, antiretroviral therapy (ART) reduces the infectivity of HIV-
positive patients, with some evidence that patients with an undetectableviral load (VL)havea negligible 
HIV-transmission risk [1,2]. In 2011, the HPTN052 trial demonstrated that initiating ART between 350-
550 CD4, i.e. earlier than recommended by the World Health Organization (WHO) guidelines, had a 
96% preventive effect against HIV transmission among stable serodiscordant couples [3].This 
evidence strengthened the Treatment as Prevention (TasP) concept, under which providing ART to all 
HIV infected patients, regardless oftheir CD4 count, might decrease HIV transmission among the 
general population in such an extent that it would curtail the HIV pandemic[4,5].Results of TasP 
randomized controlled trials are not expected before several years [6]. Meanwhile, there are still 
questions regarding factors that might impact the effect of early ART in the general population and 
make this effect different from that observed in the very specific group of stable serodiscordant 
couples.  
Among these factors, the impact of early ART on risky sexual behaviors is one of major 
concern. In the first years of the highly active ART era, increased risky sexual behaviors associated 
with ART were reported among high-risk groups [7,8]. Risk compensation related to decrease in 
perception of HIV transmission risk and severity of HIV infection may potentiallyoffset the protective 
effect of early ART [9,10]. Nevertheless, a recent review of observational studies conducted in 
developing countries rather suggested a decrease in risky sexual behaviors after ART initiation [11]. 
However, such studies may be subject to confounding. In addition, only few of themwere prospective 
[12], and all were conducted in thecontext of standard ART initiation [11,13]. Starting ART earlier,in 
healthy patients, may impact on sexual behaviors differently. Updating results about this issue, 
especially in the current context of early ART initiation, is thus needed[14]. 
Evidence obtained so far has resulted in WHO recommendations of early ART for prevention 
specifically for the population of serodiscordant couples[15].Nevertheless, according to a recent 
estimation, only less than a third of new HIV transmissions in sub-Saharan Africa occurs among these 
couples [16]. This suggests that programs targeting solely stable serodiscordant couples may lack to 
prevent the majority of new infections. Estimating the preventive effect of early ART beyond the 
population of stable serodiscordant couples is thus of great interest for scaling-up effective prevention 
strategies. 
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Relying on data from the ongoing Temprano-ANRS12136randomized controlled trial, we 
aimed to measure the impact of early ART initiation on sexual behaviors and to estimate itsprotective 
effect among a West African adult population reporting diverseheterosexual partnership status 
(serodiscordant or concordant, stable or casual). 
 
MATERIAL & METHODS 
  
Temprano-ANRS12136 trial 
 Temprano is a multicenter randomized open-label superiority trial to assess the benefits and 
risks of initiating ART earlier than currently recommended by WHO, concomitantly or not with a 6-
month isoniazide prophylaxis for tuberculosis (IPT). The trial was launched in March 2008 in Abidjan, 
Côte d‘Ivoire, and is still ongoing. The trial protocol was approved by the ethics committee of the 
Ministry of Health of Côte d‘Ivoire and by the institutional review board of the French National Agency 
for Research on AIDS and viral hepatitis (ANRS, Paris, France). It has been registered on 
clinicaltrials.gov under the following identifier: NCT00495651. 
 Between March 2008 and July 2012, patients attending 9 care centers in Abidjan were 
included in the trial whenever they met the following criteria: signed informed consent; age>18 years; 
HIV-1 or HIV 1+2 dual infection; no ongoing active tuberculosis; no ongoing pregnancy or 
breastfeeding; CD4 count<800 cells/mm
3
 and no criteria for starting ART according to the most recent 
WHO guidelines. Participants were randomized into four arms: two ―standard ART‖ arms (arm 1 and 
2), in which ART wasdelayeduntil patients meet ongoing WHO starting criteria[17,18]; and  two ―early 
ART‖ arms(arm 3 and 4), in which ART was initiated immediately on inclusion. In arm 2 and arm 4, 
participants received a 6-month IPT, starting at the Month-1 visit and stopping at the Month-7 visit.  
Once included, participants were asked to show up for trial scheduled visits every 3 months. CD4 
count and plasma HIV-1 RNA (real-time PCR, Taq Man technology Abi Prism 7000, Applied 
Biosystems, detectability 300 copies/mL) were measured every 6 months.Each participant was to be 
followed during 30 months. The main outcome of the trial is the occurrence of a new episode of severe 
morbidityand any event leading to death. 
 
Socio-behavioral study 
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The present socio-behavioral study was nested in the Temprano trial. All participants included 
in Temprano between January 1
st
 2009 and September 1
st
 2011 were eligible for the study. A 
standardized questionnaire was used to collect information on sexual behaviors. Participants 
completed this questionnaire face-to-face at the 12-month visit (M12). 
 
Study outcomes 
Sexual behaviors of interest included sexual activity and multiple partnerships in the past year, 
and characteristics of the last sexual intercourseincludingdate (occurred in the past month/past year), 
type of partnership (cohabiting or not) and partner‘s HIV status (unknown/negative/positive). 
 Risky sex at last sexual intercourse in the past month was defined as an unprotected 
intercourse with a partner of HIV negative/unknown status. Partner‘s exposure to HIV infection was 
defined as risky sex associated with a measure of VL≥300 copies/mm
3
 at the time of the intercourse, 
i.e. within a period ranging from 30 days before to 7 days after thedate of completion of the socio-
behavioral questionnaire. 
For each sexually active participant, a HIVtransmission risk for the lastintercourse in the past 
month was calculated based onreported partner‘s HIV status, condom use and VL measured at the 
time of the intercourse. Per-coital-act VL-specific probabilities of transmission were derived from a 
seroconversion study of HIV-discordant couples in eastern and southern Africa [19], using the 
following formula: 
p  = 1 −  𝑒−𝑒
 −7.257 +1.070∗ 𝐿𝑜𝑔  𝑉𝐿  −4 −0.025 ∗ 𝑎𝑔𝑒 −35  
 
where p is the per-coital probability of HIV transmission (J.P. Hughes, personal communication). 
Patients with undetectable VL were assigned a null transmission risk [2]. We attributed a 78% 
transmission risk reduction if condom was reported, and, for female participants, we considered each 
last sexual male partner as circumcised (96% of men actually are in Côte d‘Ivoire [20]) and thus 
applied a 53% transmission risk reduction [19]. Partners with unknown HIV status were considered as 
HIV-uninfected. For a partner reported as HIV-positive, transmission risk was set to zero. 
We estimated HIV-transmission rates at last sexual intercourse in the past month for both ART 
strategies by computing means of individual transmission risks, expressed per 10,000 sexually active 
individuals. 
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In order to estimate transmission rates in the whole studied population and not only among 
sexually active persons, we computed an additional estimation including participants sexually inactive 
in the past month, attributing them a null individual transmission risk.  
 
Statistical analysis 
Participants included in the Temprano trial between January 1
st
 2009 and September 1
st
 2011 
were included in the analysisprovided they completed the 12-monthsocio-behavioral questionnaire in 
due time  (±3 months). 
Analyses were conducted in intention to treat. Sexual behaviors of interest were compared 
between early ART and standard ART strategies using Chi-2 tests. The protective effect of the early 
ART strategy on HIV-transmission risk was based on the ratio of transmission rates. 
To assess the robustness of our estimates, we conducted a range of sensitivity analyses, 
considering:  (i) only participants with baseline CD4>350/mm
3
; (ii) only those engaged in a cohabiting 
serodiscordant relationship; (iii) a non-null transmission probability for those having a VL<300 
copies/mm
3
[21]; (iv) an alternative dataset for VL-specific transmissions probabilities[22]; (v) a 
probability of 0.4 to be HIV-positive for a sexual partner with unknown serostatus; (vi) all participants 
as having had a last unprotected intercourse with a HIV-negative partner. 
All analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North Carolina, 
USA). We computed 95% Confidence Intervals for expected transmission rates and protective effect of 
early ART using bootstrap (10,000 re-sampling). 
 
 
RESULTS 
 
Study population 
Among the 1172participants included in the Temprano trial between 1
st
 January 2009 and 1
st
 
September 2011, 957 (81.7%) were included in the analyses(standard ART: 467; early ART: 490). 
Participants on early and standard ART attended a similar mean number of trial medical visitsbetween 
enrollment and 12 months (standard ART: 5.9; early ART: 6.2). 
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The remaining 215 were excluded (standard ART: 123vs. early ART: 92; p=0.03) for the 
following reasons:deathwithin the first 12 months (6vs. 9, respectively;  p=0.42); not showing up for 
12-month visit (17vs.38, respectively; p=0.003);12-month socio-behavioral questionnaire not or 
untimely completed (standard ART: 93, of which 59 had initiated ARTbefore the 12-month visit; early 
ART: 30; p=0.02). 
Participants included in the study did not differ from those excluded regarding socio-
demographic characteristics, except for schooling (at least secondary level: included 47.1%, excluded 
38.1%; p=0.02). 
Among the 957 participants, a large majority (80.4%) were women. At baseline, median age 
was 35 years and 442 participants (46.2%) were living in union. Neither baseline socio-demographic 
and clinical characteristics (Table 1) nor baseline VL distributions (Wilcoxon rank-sum test: 0.53; 
Figure 1a)significantly differed between participants on early vs. standard ART. 
At the 12-month visit, 70 (15.0%) patients in standard ART had initiated ART (median duration 
between inclusion and ART initiation: 9.5 months). Overall, VL measured at 12-month was available 
for 427 (91.4%) patients on standard ART and 468 (95.5%) on early ART.As expected, due to the 
difference in ART coverage, the percentage of patients with undetectable VL was significantly lower in 
those on standard ART vs. early ART (Wilcoxon rank-sum test: p<10
-3
; Figure 1b). 
 
Sexual Behaviors, Risky Sex and Partner‘s Exposure to HIV infection at 12-month visit 
Sexual behaviors in the past 12 months are presented in Table 2. No significant difference 
was observed between patients on standard vs. early ART in the proportions of sexual activity 
(standard ART: 71.7% vs. early ART: 69.8%; p=0.51) and multiple partnerships (6.2% vs. 9.0%, 
respectively; p=0.11) in the past year. Among sexually active participants, 41.2% vs. 41.8%, 
respectively, reported they were not cohabiting with their last sexual partner (p=0.87). Overall, the last 
sexual partner was reported to be HIV-uninfected by 26.6% vs. 22.8% of sexually active participants, 
respectively; and to have an unknown HIV-status by 43.9% vs. 47.7%, respectively (p=0.47). 
Characteristics of the last intercourse in the past month are presented in Table 3. Participants 
on standard vs. early ART did not significantly differ as regard to sexual activity in the past month and 
condom use. Risky sex was reported by 12.8% of participants in standard ART vs. 10.0% in early ART 
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(p=0.54). When taking into account last available VL, the proportions of participants exposing their 
partner to HIV infection were 10.7% vs. 2.4%, respectively (p<0.001). 
 
Estimated HIV-transmission rates at 12-month visit 
Figure 2a shows the estimated HIV-transmission rates per 10,000 sexually active persons at 
last sexual intercourse in the past month, based on risk behaviors and VL data, for both ART 
strategies. Theestimated transmission ratewas 4.0/10,000 (95% Confidence Interval, 95%CI: 3.0-5.0) 
among those onstandard ARTand 0.5/10,000 (95%CI: 0.2-0.8) among those on early ART. The 
corresponding estimated protective effect of early ART against HIV transmission was 89% (95%CI: 
79-95%).When including all participants in the computations (Figure 2b), the estimatedtransmission 
ratewas 1.9/10,000 (95%CI: 1.4-2.4) in those on standard ARTvs.0.2/10,000(95%CI: 0.1-0.3) in those 
on early ART, representing a protective effect of 90% (95%CI: 81-95%). 
Results of sensitivity analyses are presented in Table 4. Whereas estimates of transmission 
rates varied substantially across scenarios, the estimated protective effect of early ART remained 
robust (ranging from 84 to 90%).  
Relying on the estimated distribution of coital frequency previously reported among 
serodiscordant couples [22], we assumed a monthly number of 8 sexual intercourses for those 
sexually active in the past month (zerofor those inactive) and extrapolated the characteristics reported 
for the last intercourse to all intercourses. Based on this assumption and on our estimate of 
transmission rates at last sexual intercourse calculated in the whole studied population, we estimated 
that early ART, compared to a standard ARTstrategy, could prevent 13.4 (95%CI: 9.4-17.7) infections 
for 10,000 patients during the 12
th
 month following early ART initiation. By extrapolating this monthly 
number to the whole M0-M12 period, we estimated that early ART could prevent 161 (95%CI: 113-
212) infections for 10,000 patients in their first year of treatment (based on estimated incidence rate of 
18.7 infections /10,000 persons-years [PY] in early ART and 179.0/10,000 PY in standard ART).  
 
 
DISCUSSION 
In this study, nested in an ongoing randomized trial of early ART, patients who started ARTat 
high CD4 counts and those who delayed ART initiation until WHO criteria are met declared similar 
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sexual behaviors at 12 months. Early ART was estimated to decrease by 90% the risk of HIV 
transmission to partners. This estimated risk reduction, which accounted for well-identified 
determinants of HIV transmission including VL, sexual partnership, condom use and circumcision[19], 
was mainly attributable to differences in VL levels between patients on early vs. standard ART.In 
contrast with previous studies that demonstrated the protective effect of ART among the sole 
serodiscordant stable couples, these estimates were derived from a diverse population with a wide 
range of partnerships and of partners‘ HIV status. More than half of our patients were not in a 
cohabiting relationship, and about two thirds of those sexually active reported a last partner with HIV-
negative or unknown status. 
The first very original finding of this study is about sexual behaviors in patients on early ART, 
which were comparable to those reported by patients on standard ART 12 months after inclusion. The 
sample size was large enough to allow the detection of a 5% difference (from 5% to 10%) between 
both ART strategies with a power of 0.95. Overall proportions of sexual activity in the past year (71%) 
and unprotection at last intercourse (25.4%) were consistent with figures previously reported inCôte 
d‘Ivoirein patients treated at late stages of HIV infection [23–25]. To our knowledge, no data on sexual 
behaviors in the context of early ART has been publishedto date. 
According to a recent review conducted in developing countries, decrease in unprotected sex 
was observed in 16 over 17 observational studies among patients on standard initiated treatment[11]. 
Such a decline in unprotected sex associated with ART may be explained by the multiple medical 
encounters that treated patients have with the care system, which ensures a high level of prevention 
counseling and psychosocial support [25,26]. In routine, contacts with the care system are often rare 
for patients non-eligible for ART [27].In our study, participants inearly and standard ART strategiesboth 
had a high frequency of contact with medical care, which may explain comparability in self-reported 
sexual behaviors. Because data reported in the standard ART initiation context show that sexual 
behaviors changes may occur over a long time period [28], sexual behaviors changes in relation with 
early ART initiation deserve to be further assessed on the long term. 
We used three different indicators to estimate HIV-transmission risk and its reduction. First, 
the proportion of last sexual intercourses exposing the partner to HIV infection based on the plasma 
VL level. This proportion was significantlylower among participantson early vs. standard 
ART.Proportions of unprotected intercourses with serodiscordant partners regardless of VL level were 
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not significantly different between both ART strategies. This suggests that the protective effect of early 
ART compared to a standard strategy principally lies on the biological effect of the treatment on viral 
replication rather than on a combination of biological and behavioral effect, as suggested by 
others[11]. 
Our second estimate of HIV-transmission risk was the expected number of transmissions at 
last intercourse in the past month, combining sexual behavior (condom use, partner‘s HIV status, and 
circumcision), exact VL values and HIV-1 transmission probabilities from the literature[19]. This 
methodology has been recently used and showed consistent results as compared to a seroconversion 
study [29]. Based on it, we estimated a protective effect of early ART of 90%. The magnitude of the 
protective effect we found was remarkably consistent across populations considered in the analysis, 
changes in our assumptions and variations in the parameters (Table 4), arguing for the robustness of 
our estimate. Moreover, this protective effect was close to those estimated in the HPTN052 study 
(96%) [3] and in a systematic review of prospective studies among discordant couples (91%, 95%CI: 
79-96%) [30].  
Third, we assessed the protective effect of early ART by computing the number of infections 
averted yearly for 10,000 persons after one year of treatment, which we estimated between 113 and 
212. Those results rely on strong assumptions regarding the frequency of sexual intercourses and the 
stability over time of the ART preventive effect in the first year of treatment. Despite the uncertainty 
surrounding these assumptions, our results are quite consistent with previous studies. The sensitivity 
analysis we conducted on the sub-sample of stable serodiscordant couples  allowed us to estimate 
HIV-incidence rateswhich were in the same range than those reported by the HPTN052 study [3]. 
Moreover, a previous model estimated that providing early (350<CD4<500) ART to serodiscordant 
couples might be expected to avert 210 infections per 10,000 person-years on ART [31]. Our estimate 
of 161/10,000 is lower, which is consistent with the fact that our study included a broader population 
than serodiscordant couples, among which a substantial part (those sexually inactive and/or engaged 
in seroconcordant partnerships) do not benefit from the preventive effect of ART. 
Our results were obtained in a population with early HIV diagnosis engaged in a 30-monthtrial. 
The sex ratio was unbalanced in favor of women, which reflects both the sex-specific prevalence of 
HIV (6.4% and 2.9%, respectively [20]) and delayed diagnosis among men, who have lower 
opportunities of early diagnoses than women in Côte d‘Ivoire [32].Even if participants of the present 
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study potentially constitute a compliant population engaged in a trial offering good care conditions, the 
proportion of viral suppression achievement in participants on early ART 12 months after enrollment 
(83%) was not dramatically higher than that documented in population-based studies throughout sub-
Saharan Africa [33]. This suggests that our results are likely to be in the range of figures observed 
more widely in West-Africa. 
Our study has some limitations. 
First, the present behavioral study was nested in a randomized controlled clinical trial which 
primary objective was to measure the individual rather than collective benefits and risks of early ART. 
Thus, before the implementation of the 2012 WHO guidelines [15], our results were obtained in the 
absence of specific information message about the preventive effect of ART. The current study may 
therefore only partially address the issue of risk compensation. Further research questioning risk 
perception in the context of widely available information about preventive effect of early ART is 
needed, both among HIV-infected and uninfected people. 
Second, the results of this study largely rely on self-reported sexual behaviors, which are 
potentially subject to social desirability bias. Over-report of condom use could lead to an 
underestimation of the estimated HIV transmission risks. However, since counseling and follow-up 
were similar between both ART groups, such a bias is unlikely to be differential and thus to have 
affectedour estimate of the preventive effect of early ART.  
Third, estimates of HIV transmission risk were based on the characteristics of the last sexual 
intercourse. This might have biased the analysis if the frequency of sexual intercourses differed 
between both groups, and/or if there were differencesbetween groups in the extent to which the last 
sexual intercourse reflected overall sexual behaviors. Such differences are unlikely, though, given that 
both groups were comparable forvarious indicators, including sexual activity and multiple partnerships. 
Fourth, differences between ART strategies in the proportionof non-response to the M12 
questionnaire might have biased estimations of HIV-transmission risk. Alowerproportion of participants 
on standard vs. early ART completed the questionnaire during the considered window period, i.e. 
between M9 and M15. Patients who completed the questionnaire out of this periodwere mostly 
individuals randomized to standard ART, who initiated ART during the first 12 months of follow-up, 
which rescheduled subsequent visits and questionnaire completions from the date of ART initiation. 
Compared to other patients on standard ART, patients who started treatment before the 12-month 
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visitprobably had higher VL, and therefore higher infectiousness, in their pre-ART period; and then 
lower VL and infectiousness in their ART-period. When considering the whole M0-M12 period, 
excluding these patients may have led to limited bias in the estimates of the transmission risk among 
those on standard ART and of the protective effect of early ART.In addition, missing 12-month visit 
during the window periodwere more frequent among patients on early ART(38 vs. 17). In 2011, 
because of the political crisis faced by Côte d‘Ivoire, the Temprano staff anticipated violence in Abidjan 
and predictable disruption of health services by giving in advance a higher stock of drugs to patients 
[34]. Thus, treated patients might have delayed their 12-month visit without being necessarily out of 
treatment. 
Expanding ART coverage has resulted in decreased HIV incidence in South Africa [35], but 
other ―natural experiments‖ showed limited effecton HIV transmission, especially when risk 
compensation was observed [36]. Community trials have started to formally assess the effect of early 
ART on HIV incidence, but their results will not be released before several years. Meanwhile, our 
results suggest a strong protective effect of early ART on HIV heterosexual transmission without any 
detectable effecton sexual behaviors. This effect was estimated in a population including substantial 
proportions of persons out of stable partnership or with a seroconcordant partner, thus closer to the 
whole HIV-infected population than previous studies restricted to stable serodiscordant couples. WHO 
has recently recommended early ART initiation for people living in serodiscordant couple [15]. The 
social acceptability and equity of prioritizing access to early ART to this population is questionable 
though[37]. Recent modeling studies on the contribution of HIV-transmissions occurring among stable 
serodicordant couples to the global sub-Saharan HIV epidemics demonstrated that prevention 
interventions targeted solely on those couples may have a limited  public health impact [16,38]. Our 
results provide evidence for the public health significance of early ART initiation among a wider 
segment of the HIV-infected population. 
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Chenal, Marcelle Daligou, Denise Hawerlander. 
– Centre National de Transfusion Sanguine (CNTS): Lambert Dohoun, Seidou Konate, Albert 
Minga, Abo Yao.  
– Unité de Soins Ambulatoires et de Conseil (USAC): Constance Kanga, Koulé Serge, Jonas 
Séri, Calixte Guéhi, Fassiri Dembélé. 
– Centre de Prise en Charge et de Formation (CePReF): Eugène Messou, Amani Anzian, 
Joachim Gnokoro, Patrice Gouessé. 
– La pierre angulaire: Madeleine Kadio-Morokro, Alain Kouadio, Séna Gountodji, Ediga Yédjédji, 
Alexis Amian 
– Hôpital Général Abobo Nord: Emmanuel Kouamé, Dominique Koua, Solange Amon, Laurent 
Dja-Beugré, Amadou Kouamé 
– FSU Anonkoua kouté: Oyéounlé Makaïla, Mounkaila Oyébi, Stanislas Sodenougbo, Nathalie 
Mbakop  
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Centre de santé El Rapha: Babatundé Natanael, Babatundé Carolle, Gisèle Bléoué, Mireille 
Tchoutchedjem 
Biology: Centre de Diagnostic et de Recherches sur le SIDA (CeDReS), CHU de Treichville, Abidjan, 
Côte d‘Ivoire: Matthieu Kabran (bacteriologist),  Arlette Emieme (monitor), André Inwoley 
(immunologist), Hervé Menan (parasitologist), Timothée Ouassa (bacteriologist), Thomas-d‘Aquin Toni 
(virologist), Vincent Yapo (virologist); Service de Virologie, CHU Necker, Paris, France: Marie-Laure 
Chaix (virologist), Christine Rouzioux (virologist).  
Trial coordination team: Programme PACCI, Abidjan, Côte d‘Ivoire: Xavier Anglaret (principal 
investigator), Christine Danel (coordinator), Raoul Moh (coordinator), Romuald Konan (pharmacist), 
Anani Badjé (monitor), Jean Baptiste N‘takpé (monitor), Gérard Menan Kouamé (monitor), Franck 
Bohoussou (data manager); Centre Inserm 897, Bordeaux, France: Delphine Gabillard (statistician), 
Jérôme Le Carrou (monitor). 
Trial Steering Committee: Jean-Marie Massumbuko, Emmanuel Bissagnene, Géneviève Chêne, 
Kouao Domoua, Mireille Dosso, Pierre-Marie Girard, Vincent Jarlier, Christian Perronne, Christine 
Rouzioux, Papa Salif Sow, Virginie Ettiegne-Traoré.  
Trial Independent Data Safety Monitoring Board: François-Xavier Blanc,Dominique Costagliola, 
Brigitte Autran, Ogobara Doumbo, Sinata Koula-Shiro, Souleymane Mboup, Yazdan Yazdanpanah 
Representatives of the French Agence Nationale de Recherches sur le SIDA (ANRS, Paris, 
France): Jean-François Delfraissy, Brigitte Bazin, Claire Rekacewicz, Géraldine Colin. 
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FIGURES& TABLES 
 
Figure 1:Distribution of plasma HIV-1 RNA, in log10copies/ml by ART strategy. Expressed as 
Log10 (VL);a) At baseline. Standard ART: undetectable VL: 4.3%; detectable VL: mean(log10 
copies/ml) [95%IC] =4.60 [4.52-4.68]. Early ART: undetectable VL: 4.1% detectable VL: mean(log10 
copies/ml ) [95%IC] = 4.63 [4.55-4.71]. b) 12 months after inclusion. Standard ART: undetectable 
VL: 12.5%; detectable VL: mean(log10 copies/ml ) [95%IC] = 4.68 [4.60-4.76]. Early ART: undetectable 
VL: 82.9% detectable VL: mean(log10 copies/ml ) [95%IC] = 3.88 [3.66-4.11]. 
 
Footnotes: log10 (HIV-1 RNA) <2.48 corresponds to the detectability threshold of HIV-1 RNA<300 copies/mL 
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Figure 2:EstimatedHIV-transmission rates at last sexual intercourse in the last month, by ART 
strategy. Socio-behavioral study nested in the Temprano trial, M12 visit (N=957). a) for 10,000 
sexually active participants, b) for 10,000 participants. 
 
Footnotes: Per-act VL-specific transmission probabilities are derived from Hughes et al., 2012 [19]. Calculation 
accounted for sexual activity, condom use, circumcision and partner‘s HIV status. 
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Table 1:Baseline characteristics, by ART strategy.Socio-behavioral study nested in the Temprano 
trial (N=957). 
  Standard ART 
strategy 
Early ART  
  N=467 N=490 p 
  n (%) n (%)  
Sex    0.78 
 Men 93 (19.91%) 94 (19.18%)  
 Women 374 (80.09%) 396 (80.82%)  
Age (years)    0.30 
 <30 118 (25.27%) 118 (24.08%)  
 30-40 217 (46.47%) 211 (43.06%)  
 >40 132 (28.27%) 161 (32.86%)  
Educational level   0.10 
 None 94 (20.13%) 131 (26.73%)  
 Primary 144 (30.84%) 137 (27.96%)  
 Secondary 170 (36.40%) 170 (34.69%)  
 >Secondary 59 (12.63%) 52 (10.61%)  
Personal source of income   0.44 
 No 116 (26.07%) 134 (28.33%)  
 Yes 329 (73.93%) 339 (71.67%)  
Family status    0.52 
 Single 200 (42.83%) 203 (41.43%)  
 Living in union 218 (46.68%) 224 (45.71%)  
 Separated/widowed 49 (10.49%) 63 (12.86%)  
Perceived health    0.12 
 Excellent/Very good 100 (21.69%) 99 (20.45%)  
 Good 298 (64.64%) 295 (60.95%)  
 Poor/Bad 63 (13.67%) 90 (18.60%)  
WHO clinical stage    0.97 
 1 290 (62.10%) 310 (63.27%)  
 2 125 (26.77%) 124 (25.31%)  
 3 50 (10.71%) 54 (11.02%)  
 4 2 (0.43%) 2 (0.41%)  
CD4 cell count /mm
3
    0.44 
 <350 71 (15.2%) 88 (17.9%)  
 350-499 176 (37.7%) 187 (38.2%)  
 ≥500 220 (47.1%) 215 (43.9%)  
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Table 2: Sexual behaviors in the past 12 months, by ART group.Socio-behavioral study nested in 
the Temprano trial, M12 visit (N=957). 
 
Standard ART Early ART p 
 
n (%) n(%) 
 
Overall N=467 N=490 
 Sexually activein the past year 335 (71.7) 342 (69.8) 0.51 
Multiple partnership 29 (6.2) 44 (9.0) 0.11 
Among those sexually activein the past year N=335 N=342 
 Last intercourse with a cohabiting partner 
  
 
Yes 197 (58.8) 199 (58.2) 0.87 
No 138 (41.2) 143 (41.8) 
 
Last partner's HIV status 
  
 
HIV-negative 89 (26.6) 78 (22.8) 0.47 
HIV-positive 99 (29.6) 101 (29.5) 
 
Unknown 147 (43.9) 163 (47.7) 
 
 
 
Table 3: Characteristics of the last intercourse in the past month, by ART group. Socio-
behavioral study nested in the Temprano trial, M12 visit (N=957). 
 
Standard ART (N=467) Early ART (N=490) p 
 
n (%) n (%) 
 
Last intercourse in the past month 226 (48.4) 214 (43.7) 0.14 
Unprotected sex at last intercourse* 100 (21.4) 76 (15.5) 0.06 
Risky sex
 1
 at last intercourse* 60 (12.9) 49 (10.0) 0.54 
Partner's exposure to HIV
 2
 at last intercourse* 50 (10.7) 12 (2.45) <10
-3
 
* Last intercourse in the past month 
1
 Unprotected sex with a partner of HIV-negative/unknown status 
2
 Unprotected sex with a partner of HIV-negative/unknown status, and HIV viral load>300 copies/mL 
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Table 4: Sensitivity analyses of estimated HIV-transmission rates at last intercourse in the past month (per 10,000 persons) and estimated 
protective effect of early ART strategy. Socio-behavioral study nested in the Temprano trial, M12 visit (N=957). 
Population Number of 
participants 
Reference for VL-specific HIV 
transmission probabilities 
Specific assumption  Expected HIV-transmissions at 
lastsexual intercourse in the past 
month, for 10,000 persons [95%CI] 
 Protective effect 
[95%CI] 
     Standard arm Early arm   
Total sample Standard arm; n=467; 
Early arm: n=490 
Hughes et al. [19] Main analysis  1.87 [1.39-2.39] 0.20 [0.09-0.33]  90% [81-95%] 
Baseline  CD4 
count>350 
Standard arm; n=396; 
Early arm: n=402 
Hughes et al. [19] Same as in the main 
analysis 
 2.03 [1.47-2.66] 0.20 [0.08-0.36]  90% [81-96%] 
Cohabiting 
serodiscordant 
couples 
Standard arm; n=55; 
Early arm: n=54 
Hughes et al. [19] Same as in the main 
analysis 
 3.36 [2.11-4.78] 0.37 [0.14-0.64]  89% [77-96%] 
Total sample Standard arm; n=467; 
Early arm: n=490 
Hughes et al. [19] VL=300 copies/mLfor 
patients with undetectable 
VL 
 1.88 [1.40-2.40] 0.30 [0.19-0.43]  84% [75-90%] 
Total sample Standard arm; n=467; 
Early arm: n=490 
Gray et al. [22] Same as in the main 
analysis 
 1.72 [1.36-2.11] 0.25 [0.14-0.4]  85% [75-92%] 
Total sample Standard arm; n=467; 
Early arm: n=490 
Hughes et al. [19] 40% of partners with 
unknown HIV status 
considered as HIV-positive 
 1.34 [1.01-1.70] 0.13 [0.07-0.22]  90% [82-95%] 
Total sample Standard arm; n=467; 
Early arm: n=490 
Hughes et al. [19] All participants considered 
as having hada last 
unprotected intercourse 
with a HIV-negative partner 
 18.4 [16.6-20.3] 2.1 [1.4-2.9]  89% [84-92%] 
 
